New Epidemiological, Clinical and Economic Data for Patients With Acromegaly in Bulgaria

Maria Kamusheva1*, Silvia Vandeva2, Konstantin Mitov1, Yanitsa Rusenova1, Atanaska Elenkova2, Sabina Zacharieva2, Zornitsa Mitkova1, Konstantin Tachkov1, Maria Dimitrova1, Miglena Doneva1, Dimitar Tcharaktchiev2 and Guenka Petrova1

1 Department of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University–Sofia, Sofia, Bulgaria, 2 Department of Endocrinology, USHATE “Acad. Ivan Penchev”, Medical University–Sofia, Sofia, Bulgaria

Background: Acromegaly and its comorbidities affect the patients’ quality of life, each healthcare system and the society. This study aimed to evaluate clinical characteristics and treatment patterns and the economic burden of acromegaly.

Materials and methods: All patients with acromegaly treated with expensive medicines and regularly followed up at the main expert clinical center for acromegaly in the country were included in this nationwide, retrospective, observational, population-based study. Patient characteristics, treatment patterns, healthcare resource use, and costs were assessed for 1-year period (01.01.2018–31.12.2018). Results were processed through statistical analysis using MedCalc software version 16.4.1.

Results: A total of 191 acromegaly patients were observed. Approximately 67% were female, 45.5% were between 41 and 60 years and the mean age at diagnosis was 40.73 years. Surgical treatment was preferred as a first-line therapy among almost 89% of all diagnosed patients. The level of comorbidities was very high as more than 95% suffered from at least one concomitant disease. The most frequent comorbidities were other endocrine and metabolic diseases (96.7%), followed by cardiovascular diseases (70.7%). The most common first-line pharmacotherapy was long-acting somatostatin analogs (SSA) (38%) followed by dual combination SSA + pegvisomant (21%). The total economic burden of acromegaly was estimated to be 2,674,499.90 € in 2018 as the direct costs (medication costs, hospitalization costs covered by the patients and the National Health Insurance Fund) outnumbered indirect costs (loss of productivity due to hospitalization): 2,630,568.58 € vs. 43,931.32 €. The average annual per-patient direct and indirect costs were 14,002.62 €.

Conclusions: The current study demonstrates a significant clinical and socio-economic burden of acromegaly in the country. Proper diagnosing and regular follow up of acromegaly patients in a specialized pituitary center ensure appropriate innovative pharmacotherapy with achievement of disease control.

Keywords: acromegaly, costs, epidemiology, treatment, Bulgaria
INTRODUCTION

Acromegaly is a rare chronic debilitating disease affecting 2–11 people per million annually. Worldwide, the prevalence of acromegaly is in the range of 28–137 cases/million population (1). According to an epidemiological study carried out in 2010, the estimated prevalence in Bulgaria is around 49 cases/million (2). Currently, the annual number of Bulgarian health insured patients with acromegaly or pituitary gigantism, whose therapy is covered by the National Health Insurance Fund (NHIF), is up to 200 (3).

Growth hormone hypersecretion is related to numerous comorbidities leading to increased mortality due to cardiovascular, cerebrovascular and respiratory diseases (4). In the last years, it became evident that in patients with long follow up cancer displaces cardiovascular diseases as a main cause of death (5–7). However, achievement of disease control restores life expectancy to levels similar to the general population (8, 9). On the other hand, acromegaly has a negative impact on health-related quality of life that barely changes after achievement of remission (10). All these highlight the need for prompt diagnosis, strict control and provision of the most appropriated therapy through close monitoring.

Acromegaly and its comorbidities affect negatively not only the patients’ quality of life but also each healthcare system and the society as a whole. An assessment of the real economic and clinical burden of acromegaly is essential for patients and their families, healthcare providers, decision-makers and society. Moreover, the entrance of innovative treatment for acromegaly requires timely and regular pharmaco-economic evaluations. A systematic review performed by the authors of the current manuscript presented the available economic evaluations in the literature (11). In fact, a wide range of studies was identified over a period of 20 years. The studies found in the literature focus more on the cost-effectiveness of the innovative therapies whereas the number of costs of illness studies, especially in some regions such as Central and Eastern European countries (CEEK) region, is scarce. Cost of illness studies or cost analysis describing the economic burden of acromegaly in the CEEC regions are published only for 2 countries: Poland (12, 13) and Bulgaria (14, 15). However, the number of costs of illness studies and other economic evaluations about acromegaly and acromegaly treatments in Bulgaria is still insufficient. Only 2 studies presented as posters at conferences were identified in the literature (14, 15). This enhanced our interest to carry out a more comprehensive study aiming to evaluate clinical characteristics, treatment patterns, and the economic burden of acromegaly.

MATERIALS AND METHODS

Study Design
An observational retrospective study was conducted among acromegaly patients diagnosed, treated and monitored in the reference center for rare endocrine diseases in the country in 2018.

Setting, Patient Recruitment and Sample Size
All patients treated for acromegaly in were included in the study. The hospital is the only pituitary center in the country supporting a computerized register for patients with acromegaly on SSAs and Pegvisomant treatment, which allowed us to include all patients in the country. The study period was 01.01.2018–31.12.2018.

Characteristics and Clinical Outcomes
The collected data included demographic characteristics (age, gender); clinical data (acromegaly duration; year of diagnosis, insulin-like growth factor 1 (IGF-1)- and growth hormone (GH)- levels at the first and last hospitalization for 2018, response to applied therapy, remission rate); level of adherence to the prescribed therapy; pharmacotherapy and other therapy: surgery and/or radiotherapy (2018); comorbidity; healthcare resources utilization (hospitalizations per year; medicines utilized); days off work due to acromegaly. Clinical data was gathered from the patients’ medical records (data in the electronic database and patients’ paper files). Disease control was considered with achievement of normal age-adjusted IGF-1 values.

Health Economic Outcomes
Direct costs (for medicines, hospitalization) and indirect (days out of work due to illness) costs were calculated on the basis of a bottom-up (micro-costing) approach. Healthcare resources consumed by the acromegaly patients included in the study were identified, measured and valued. Pharmacotherapy monthly costs paid by the National Health Insurance Fund (NHIF) and by the patients were presented separately. They were calculated in two time periods: before the first hospitalization in 2018 and after the last hospitalization in 2018. Hospitalization costs were calculated taking into account the number of hospitalizations per patient per year and the National Framework Contract for payment of medical services signed by the NHIF and the Medical Union, 2018.

Reimbursement levels and the price per unit paid by the NHIF for all included in the Positive Drug List medicines for acromegaly patients (ICD E22.0) were considered. The unit medicines costs were obtained from the Positive Drug List, and for the other resources from the National Health Insurance Fund website and National Statistical Institute reports. All calculated pharmacotherapy costs (monthly cost and annual cost), indirect costs (annual cost) and hospitalization costs per year were presented in euro adjusted for the purchasing power parity (PPP) for 2018 (16). The nominal exchange rate from the European Central Bank was used to convert the national currency (BGN) in euro. The received values in euro were adjusted applying the purchasing power parities based on gross domestic product from the Eurostat website (7, 17, 18). It was calculated that 1 Bulgarian lev (BGN) is equal to 0.5136 PPP-adjusted euros for 2018.

Having the number of hospital days for every patient we calculated the indirect costs [days out of work (absenteeism)]
TABLE 1 | Evaluated and included in the study resources.

| Type of resources | Time period | Unit costs paid by the NHIF (PPP EUR 2018) | Unit costs paid by patient (PPP EUR 2018) | Sources of data |
|-------------------|-------------|------------------------------------------|------------------------------------------|----------------|
| **Pharmacotherapy** |             |                                          |                                          |                |
| Cabergoline 0.5 mg | 1 month     | 60.40 €                                  | 0.00 €                                  | Positive Drug List, Annex 1, 01/2018 |
|                   | 12 months   | 724.80 €                                 | 0.00 €                                  |                |
| Bromocriptine 2.5 mg | 1 month | 3.32 €                                   | 0.00 €                                  |                |
| Quinagolide | 1 month | 21.13 €                                  | 0.00 €                                  |                |
| Octreotide LAR 20 mg | 1 month | 523.01 €                                 | 195.94 €                                |                |
|                   | 12 months   | 6,276.09 €                               | 2,351.34 €                              |                |
| Octreotide LAR 30 mg | 1 month | 784.61 €                                 | 0.00 €                                  |                |
|                   | 12 months   | 9,415.27 €                               | 0.00 €                                  |                |
| Pasireotide LAR | 1 month | 2,780.49 €                               | 0.00 €                                  |                |
|                   | 12 months   | 33,365.92 €                              | 0.00 €                                  |                |
| Pegvisomant 10 mg | 1 month | 2,009.46 €                               | 0.46 €                                  |                |
|                   | 12 months   | 24,113.48 €                              | 5.53 €                                  |                |
| Pegvisomant 15 mg | 1 month | 3,014.18 €                               | 0.00 €                                  |                |
|                   | 12 months   | 36,170.19 €                              | 0.00 €                                  |                |
| Pegvisomant 30 mg | 1 month | 6,028.36 €                               | 0.00 €                                  |                |
|                   | 12 months   | 72,340.38 €                              | 0.00 €                                  |                |
| **Hospitalization** | 12 months   | 256.80 €                                 | 2.98 € per day                           | National Framework Contract, 2018 (clinical path 80.1); Decree No. 193 of the Council of Ministers, 2012 |

**Indirect costs**

| Type of resources | Time period | Number of working days per month | Average monthly earnings (PPP EUR 2018) | Sources of data |
|-------------------|-------------|----------------------------------|----------------------------------------|----------------|
| Days out of work | 12 months   | 20                               | 555.46 € PPP                           | National Statistical Institute report, 2018 |

The cost per unit of resource, the time periods for the collection of data and the sources of data for the unit costs are presented in Table 1.

The total annual direct costs paid by the public fund were found as a sum of the annual pharmacotherapy and hospitalization costs. The total costs from societal perspective presented the sum of all direct medical and indirect costs per year for all acromegaly patients.

**Statistics**

A set of statistical methods were applied to describe and assess the correlations among data of interest: descriptive statistics, non-parametric analysis Kruskal-Wallis, Wilcoxon test for paired samples, chi-squared test, and regression analysis. MedCalc statistical software version 16.4.1 for biomedical research was used. Descriptive statistics were applied to present the basic characteristics of the patients: sex, age, birthplace, age of diagnosis, type of therapy. Comparisons between the median values of different patients’ groups characteristics were performed by the Kruskal-Wallis test. Wilcoxon test was used to compare paired samples regarding the levels of IGF-1 before and after treatment, whereas the chi-squared test was useful for comparison of distributions and relationships between categorical variables (type of remission, response to therapy, etc.). Regression analysis predicted the outcomes based on historical data regarding the year of diagnosis and the number of patients diagnosed.

**Ethics**

All patients with acromegaly were asked to take part in the study. All patients with no exception provided signed written informed consent at their admission authorizing the use of their anonymized (pseudonymized) data for scientific purposes. The
local hospital ethics committee approved the study (number of approval is 4/09.08.2019).

RESULTS

Demographics

All acromegaly patients \( n = 191 \) treated in the University hospital “Acad. Ivan Penchev,” Sofia for the year 2018 were enrolled in the study. Significantly more women were affected as they represent \( \sim 67\% \) of the sample \( (p < 0.0001) \). Patients who live in urban areas are almost 3 times more than those from villages \( (p < 0.0001) \) which is in accordance with the national statistic data for the proportion of the urban and rural population in the country—1:2.8 The highest was the number of patients between 41 and 60 years of age—almost half of all enrolled \( (p < 0.0001) \) (Table 2).

### Clinical Characteristics

The mean age at diagnosis for acromegaly was 40.73 years (95% CI 38.901–42.553, SD = 12.7). There was no statistically significant difference between the median age at diagnosis for acromegaly for both genders \( (p = 0.16) \) and place of birth (city or village) \( (p = 0.5662) \). 171 patients \( (89.5\%) \) were subjected to transsphenoidal adenomectomy (TSA) and their mean age was 41.13 years (95% CI: 39.09–43.15), whereas only 18 patients at mean age of 46.33 years (95% CI: 37.85–54.82) were contraindicated for TSA due to concomitant illness or a refuse to be operated. The rest two newly diagnosed patients were referred to the neurosurgical unit for operation.

In our cohort 118 patients have been treated with SSA at some stage of their follow up. At the time of the study full response to the therapy, evaluated by normalization of IGF-1, was achieved in 59 patients (Table 3). All patients on continuous SSA monotherapy with active disease, or patients on combination therapy, including SSA and some other class of drugs, or monotherapy with Pasireotide LAR were considered as partial responders \( (n = 46) \). Patients on monotherapy with Pegvisomant or combination therapy with Pegvisomant and Cabergoline were considered as non-responders \( (n = 8) \), as all of them have previously been treated with SSA. In five patients SSA therapy was newly initiated and the therapeutic response could

| Category | Sub-group | Number [distribution in %] |
|----------|-----------|-----------------------------|
| Age      | <40 years | 35 [18.3%]                  |
|          | 40 – 60 years | 87 [45.5%]              |
|          | >60 years | 69 [36.1%]                  |
| Gender   | Male      | 64 [33.5%]                  |
|          | Female    | 127 [66.5%]                 |
| Region   | Village   | 40 [20.9%]                  |
|          | Town/city | 151 [79.1%]                 |

### TABLE 2 | Demographic characteristics of acromegaly patients population in Bulgaria \( (n = 191) \).

| Category | Sub-group | Mean age at diagnosis (years) \( n = 191 \) |
|----------|-----------|--------------------------------------------|
| Clinical data | Male | 39.08 years of age (35.9-42.25)* [SD = 12.71] |
|           | Female | 41.58 years of age (39.33-43.82)* [SD = 12.67] |
| IGF-1 levels** at the first hospitalization for 2018 | Male \( n = 29 \) | 28.7 [16.25-36.95]* [SD = 12.67] |
|           | Female \( n = 55 \) | 29.7 [17.45-37.83]* |
| IGF-1 levels** at the last hospitalization for 2018 | Male \( n = 29 \) | 28.5 [19.3-36.4]* |
|           | Female \( n = 55 \) | 22.5 [14.48-30.40]* |
| GH-levels*** at the first hospitalization for 2018 | Male \( n = 28 \) | 6.85 [2.45-10.85]* |
|           | Female \( n = 51 \) | 7 [3.73-18.9]* |
| GH-levels *** at the last hospitalization for 2018 | Male \( n = 28 \) | 4.7 [1.63-7.16]* |
|           | Female \( n = 51 \) | 4.7 [2.65-8.83]* |
| Response to Sandostatin LAR therapy \( N = 118 \) | Non-responders | 8 (6.78%) |
|           | Partial responders | 46 (38.9%) |
|           | Responders | 59 (50.0%) |
| Remission rate \( N = 191 \) | Active disease | 30 (15.7%) |
|           | Disease control | 161/191 (84.3%) |

** Includes information about health-related quality of life (HRQOL), symptoms, function, satisfaction with care or symptoms, adherence to prescribed medications or other therapy, and perceived value of treatment (19).

† median value [25-75P] (hypothesis for normal distribution was rejected).
concomitant diseases Total [%] Number [%]*

No 7 [3.66%] 5 [2.62%] 1 [0.52%] 1 [0.52%]
Yes 184 [96.34%] 30 [15.7%] 86 [45%] 68 [35.6%]
>2 diseases 152 [79.6%] 12 [6.3%] 74 [38.7%] 66 [34.5%]
Only 1 disease 32 [16.8%] 18 [9.4%] 12 [6.3%] 2 [1.04%]

*Percentages are calculated as the number of patients in each group is divided by the total number of patients (n = 191).
Statistically significant difference was observed between distribution of patients according to the type of pharmacotherapy and duration of the main disease: more patients (26) diagnosed with acromegaly 1–10 years ago were on monotherapy in comparison to those diagnosed 11-20 years (13) and > 21 years (13) ago (p = 0.0357). Longer disease duration was associated with lower number of patients without therapy (4 patients vs. 15 on monotherapy and 6 on combination therapy) (p = 0.0357). Combination therapy was prescribed mainly to patients diagnosed 11–20 years ago (p = 0.0357) (Table 5, Figure 3).

**Healthcare Resources Utilization and Costs**

Logically, the costs paid by patients and the NHIF increased by elevating the number of hospitalizations and length of hospital stay (p < 0.0001) (Table 6). The length of hospital stay was longer in patients diagnosed with other endocrine disease: 8.53 days [SD = 1.9] vs. 6.15 days [SD = 3.34] as it was statistically significant (p = 0.012). Total costs for hospital stay paid by the Fund for all patients with acromegaly for 2018 were ~79 900 euro, whereas the total out-of-pocket payments for hospitalization were 4,726.29 euro (Table 6).

Mean monthly medicines costs paid by the NHIF were significantly higher for patients on combination therapy than on monotherapy: 3,565.37 €PPP vs. 753.28 €PPP, respectively (p < 0.000001). A similar result was observed for out of pocket monthly payments: 240.47 €PPP for monotherapy vs. 328.94 €PPP for combination therapy (p = 0.000001).

Total annual reimbursable costs for all acromegaly patients are almost 2,280,000.00 €PPP. Total patients’ costs per year reached 270,500.00€PPP.

Median monthly NHIF reimbursement pharmacotherapy costs paid per patient were 784.59 €PPP (95% CI 523–1045.99, SD = 1784.07) while out of pocket pharmacotherapy payments were 195.94 €PPP (95% CI 195.94–319.18, SD = 107.04).

Pharmacotherapy costs varied in a wide range depending on the type of therapy and prescribed dosage scheme: Octreotide LAR could be prescribed in doses of 20 mg, 30 mg or 40 mg per month given I.M. intraglutely. Pegvisomant is administered by daily subcutaneous injection at three possible doses: 10, 15 or 30 mg per day etc. Therefore, the average costs presented in Figure 4 differ significantly as the highest were the NHIF costs for triple combination (SSA+Pegvisomant+DA) 5,440.36 €PPP, followed by monotherapy with Pegvisomant (4,521.18€PPP) prescribed in higher dose in comparison with combination therapies SSA+Pegvisomant (4,455.50 €PPP) or Pegvisomant+DA (3,554.73 €PPP).

Total direct (hospitalization and pharmacotherapy) and indirect costs are presented in Figure 5 as the pharmacotherapy costs covered by the NHIF (85.08%) far outnumber the other costs (14.92%).

**DISCUSSION**

The current study presents the demographic and clinical characteristics of acromegaly patients and evaluates the available
Table 5: Acromegaly pharmacotherapy in Bulgaria by type of therapy and by INN.

| Category                                           | Number [distribution in %] |
|---------------------------------------------------|----------------------------|
| **Pharmacotherapy by type at first hospitalization in 2018 (n = 191)** |                           |
| Monotherapy                                       | 88 [46%]                   |
| Combination therapy                               | 40 [21%]                   |
| No therapy                                        | 63 [33%]                   |
| **Pharmacotherapy by INNs*** at first hospitalization in 2018 (n = 191)** |                           |
| DA*                                               | 10 [5.3%]                  |
| SSA**                                             | 73 [38.2%]                 |
| Pegvisomant                                       | 2 [1.1%]                   |
| SSA+DA                                           | 9 [4.7%]                   |
| Pegvisomant + SSA                                 | 22 [11.5%]                 |
| Pegvisomant+DA                                    | 6 [3.2%]                   |
| SSA+DA+Pegvisomant                                | 3 [1.6%]                   |
| Pasireotide LAR                                   | 3 [1.6%]                   |
| **Pharmacotherapy by type at last hospitalization in 2018 (n = 188)** |                           |
| Monotherapy                                       | 91 [48.4%]                 |
| Combination therapy                               | 39 [20.7%]                 |
| No therapy                                        | 58 [30.9%]                 |
| **Pharmacotherapy by INNs at last hospitalization in 2018 (n = 188)** |                           |
| DA*                                               | 12 [6.3%]                  |
| SSA**                                             | 74 [39.4%]                 |
| Pegvisomant                                       | 2 [1.06%]                  |
| SSA+DA                                           | 9 [4.8%]                   |
| Pegvisomant + SSA                                 | 21 [11.2%]                 |
| Pegvisomant+DA                                    | 6 [3.2%]                   |
| SSA+DA+Pegvisomant                                | 3 [1.6%]                   |
| Pasireotide LAR                                   | 3 [1.6%]                   |

*DA, dopamine agonists; **SSA, somatostatin analogs; ***INNs, international nonproprietary names.

It was revealed that Bulgarian female patients with acromegaly were almost double than male (127 vs. 64) and those between 41 and 60 years prevailed—45.5%. Some published studies found the same difference in the frequency according to patients’ gender (23–25) while in others both genders were affected equally (26–28). We found that the mean age at diagnosis for acromegaly was 40.73 years in Bulgaria which is in accordance with the literature data (between 40 and 50 years of age) (24, 29–31).

The number of patients diagnosed with acromegaly in Bulgaria is increasing following exponential trend established in an analysis over a long period of time: 1975–2018. This might be explained with improved diagnostic tests, widespread use of magnetic resonance imaging (MRI) (32) and increased awareness for this specific group of patients. The exponential regression model could be used for the purposes of prognostic analysis of the expected number of acromegaly patients and related costs for diagnosis, surgery, hospitalization, treatment, and follow up in the near future. Further studies focusing on incidence should be provided so as to clarify this tendency.

Surgical treatment (TSA) was preferred as a first-line therapy in almost 90% of our patients. Similar figures were reported from our nationwide database (2, 33), as well as in numerous national registries (Finland (31), Italy (34), Spain (35), Canada (36), South Korea (37), Germany (38), France (7), Mexico (39)). Radiotherapy was performed in 16.7% of all 191 patients, in contrast to the data from our registry, where close to 30% of all patients were irradiated. Similar tendency for reduction of the use of radiotherapy has been observed in several registries (7, 26, 31, 36). It could be explained by the introduction of highly effective medical treatment, such as SSA and Pegvisomant, leading to improved biochemical control. However, in our cohort the number of irradiated patients could be underestimated as the study period is only one year and presumably patients with stable disease control after radiotherapy visit our clinics less frequently.

Pharmacological treatment was applied in 68% of our cohort. This figure could be overestimated in terms of giving a representative picture of the whole country due to the presence of less frequently followed up patients. However, as SSAs and Pegvisomant are prescribed only in our center, our study presents all patients in the country on these medications. Long-acting SSAs was the most prescribed therapy (61.7%), as a mono- or combination therapy, in accordance with the current guidelines in the European region and Bulgaria (40). Monotherapy with SSA led to disease control in 50% (59 out of 118 patients with prescribed SSA at any time of the follow up) of our patients. We assume that it is a real-life picture as it has been a first-line therapy for all patients with persistent moderate or severe disease activity after TSA, or as a primary therapy. Our remission rates are in agreement with the results from a recent meta-analysis, showing 55% normalization of IGF-1 under long-acting SSAs (41).

Dual combination SSA + pegvisomant is the second most prescribed therapy in the observed group (10.9% of all patients). Pegvisomant was used extremely in a combination therapy – 93.7% of all patients under this treatment, in part due to cost-effective issues. Of note, an increase in the proportion of combination therapy has been observed in a recent update of the ACROSTUDY (42). The overall remission rates under treatment with Pegvisomant, as mono- or combination therapy at any point during the follow up was 82.8% which is a bit higher from other real-life data (43). It could be explained by a beneficial effect of close monitoring and prompt titration of doses in a centralized manner in a specialized pituitary center. This speculation can be valid for the overall remission rates of our cohort of 82.3%.
Our patients suffered mostly from other endocrine and metabolic diseases (ICD E00-E90) (96.7% or 178 patients) such as diabetes mellitus, disorders of thyroid gland, hypopituitarism, hyperprolactinemia etc., followed by cardiovascular (ICD I00-I99) (70.7%) (arterial hypertension, arrhythmias, cardiomyopathy etc.) and musculoskeletal disorders (ICD M00-M99) (22%) (arthropathy, osteoarthrosis, osteoporosis etc.). In a recent study Maione et al. review data from national registries on comorbidities, the most prevalent being arterial hypertension (11–54%), type 2 diabetes mellitus (12–40%), osteoarthropathy (20–69%), and pituitary hormone deficiency (8–68%) (7). Normalization of GH and IGF-1 are essential for control of comorbidities and subsequently reduction in mortality rates, which become similar to the general population (5–7, 34). The socio-economic burden of comorbidities is a complex issue and deserves a more detailed study.

The economic evaluation of acromegaly was performed among 191 patients and it is the first common study that gathered information for all diagnosed and treated in 2018.
The economic burden of acromegaly was estimated to be 2,674,499.90 € in 2018 as the annual per patient costs are approximately 14,002.62 € taking into account direct and indirect costs. Another Bulgarian study among smaller group of acromegaly patients calculated that total direct costs per patient per year are around 14,800.00€ which is a little bit higher probably due to the sample size (15). A Swedish study calculated higher annual costs equal to 6,328,000.00€ in 2013 whereas the annual per patient costs were lower – 12,000.00€ (43). Similarly to this Swedish study, we found that direct costs outnumber the indirect costs. However, we should remark that the indirect costs calculated in the current study are associated only with the days out of work due to hospitalization which underestimate the real indirect costs related to acromegaly.

Interestingly, the NHIF costs outweighed almost nine times the out of pocket payments which indicates adequate assurance of Bulgarian acromegaly patients with financial access to innovative therapies. The NHIF pays annually almost 2,270,000.00 € for acromegaly pharmacotherapy—a result similar with the results of a previously conducted Bulgarian study in which the top-down approach for costs calculation was applied (14).

To the best of our knowledge, this is the first study carried out in Bulgaria and focusing on the clinical and socio-economic burden of acromegaly. It could serve as an initial step for further national and regional longitudinal incidence-based cost of illness studies for better understanding the real impact of acromegaly from various perspectives: the societal, patients’, their families’ and the National healthcare insurance fund’s.

A strong limitation of our study is the short period of observation (only 1 year) taking into account narrow range of costs: only for medicines, hospital stay and temporary loss of productivity. Broadening the calculated costs taking into consideration presenteeism, informal care, concomitant diseases treatment, and direct non-medical costs such as transportation...
due to required health care visits, surgery costs as well as presenting more detailed analysis of the effectiveness on the basis of real-world data could bring more value to the research and could better inform the stakeholders.

Moreover, this study stresses the importance of further combined economic and clinical evaluations for other rare diseases in Bulgaria. Thus, enough economic and clinical information could be gathered for the purposes of making healthcare decisions based on valuable scientific evidence.

CONCLUSIONS

The current study demonstrates a significant clinical and socioeconomic burden of acromegaly in Bulgaria. Early diagnosis and regular follow-up of acromegaly patients in Bulgaria ensure adequate access to specialized medical care and appropriate pharmacotherapy. Bulgarian acromegaly patients have been provided with financial access to the latest innovative therapies.

DATA AVAILABILITY STATEMENT

The datasets generated for this study are available on request to the corresponding author.

REFERENCES

1. Bollerslev J, Heck A, Olarescu N. Individualised management of acromegaly. *Eur J Endocrinol.* (2019) 181:R1–R5. doi: 10.1530/EJE-19-0124
2. Vandeve S, Andreeva M, Orbetsova M, Charalakiev D, Krilov G, Elenkova A, et al. Acromegaly in Bulgaria - epidemiological characteristics derived from the national acromegaly database. *Endocrinol Clinia.* (2010) 3:142–51.
3. *National Health Insurance Fund Report.* (2017). Available online at: https://www.nhf.bg/page/218
4. Abreu A, Tovar AP, Castellanos R, Valenzuela A, Gomez Giraldo CM, Pinedo A, et al. Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. *Pituitary.* (2016) 19:448–57. doi: 10.1007/s11122-016-0725-2
5. Mercado M, Gonzalez B, Vargas G, Ramirez C, de los Monteros AL, Sosa E, et al. Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. *J Clin Endocrinol Metab.* (2014) 99:4438–46. doi: 10.1210/jc.2014-2670
6. Ritvonen E, Lütytniemi E, Jaattinen P, Ebeling T, Moilanen L, Nuutila P, et al. Mortality in acromegaly: a 20-year follow-up study. *Endocr Relat Cancer.* (2016) 23:469–80. doi: 10.1530/ERC-16-0106
7. Maione L, Brue T, Beckers A, Delember B, Petrossians P, Borson-Chazot F, et al. Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry. *Eur J Endocrinol.* (2017) 176:645–55. doi: 10.1530/EJE-16-1064
8. Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of gH and iGF-I on mortality in acromegaly. *Eur J Endocrinol.* (2008) 159:89–95. doi: 10.1530/EJE-08-0267
9. Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM, et al. Acromegaly. *Nat Rev Dis Primers.* (2015) 9:520. doi: 10.1038/nrdp.2015.019-0129-5
10. Geraedts VJ, Dimopoulou C, Auer M, Schopohl J, Stalla GK, Sievers C. Health outcomes in acromegaly: depression and anxiety are promising targets for improving reduced quality of life. *Front Endocrinol (Lausanne).* (2015) 5:229. doi: 10.3389/fendo.2014.00229
11. Kamusheva M, Rusenova Y, Vandeve S, Elenkova A, Zaharieva S, Doneva M, et al. Economic and pharmaco-economic analysis of acromegaly treatment: a systematic review. *biotech Biotechnol Equip.* (2019) 33:1560–71. doi: 10.1080/13102818.2019.1680317

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Local Ethics Committee in USHATE Acad. Ivan Penchev, Medical University-Sofia, Bulgaria (number of approval is 4/09.08.2019). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

All the authors have provided valuable contributions to the manuscript. MK and SV carried out the research and drafted the manuscript. MK and YR entered the patients’ data in a database. KM, MK, and MDo performed the statistical analysis. AE, SZ, ZM, MDi, DT, KT and GP participated in the study design and reviewed the paper. All authors read and approved the final manuscript.

ACKNOWLEDGMENTS

This work is supported by the Bulgarian Ministry of Education and Science under the National Program for Research Young Scientists and Postdoctoral Students.

12. Śliwczynski A, Brzozowska M, Labenda A, Orlewska K, Milkowski M, Orlewska E. Real-World comorbidities, treatment pattern and cost of patients with acromegaly in Poland based on retrospective analysis of administrative claims data. *Value Health.* (2016) 20:A347–A766. doi: 10.1016/j.jval.2016.09.1931
13. Elbaum M, Bolanowski M. One-Center analysis of cost associated with acromegaly management in Poland. *Value Health.* (2017) 20:A477. doi: 10.1016/j.jval.2017.08.448
14. Rusenova Y, Aimanova B, Marinova D, Kamusheva M, Petrova G. Pharmacotherapy costs for patients with acromegaly in Bulgaria. *Value Health.* (2018) 21:5451. doi: 10.1016/j.jval.2018.09.2663
15. Kamusheva M, Zaharieva S, Elenkova A, Doneva M, Dimitrova M, Petrova G. Health-Related quality of life and pharmacotherapy costs study for patients with rare endocrine diseases in Bulgaria - A Pilot study. *Value Health.* (2017) 20:A560. doi: 10.1016/j.jval.2017.08.918
16. *Eurostat Data.* Available online at: http://appsso.eurostat.ec.europa.eu/nui/submitViewTableAction.do
17. *European Central Bank.* Available online at: https://www.ecb.europa.eu/stats/policy_and_exchange_rates/euro_reference_exchange_rates/html/euroxfref-graph-bgn.en.html
18. Ignatova D, Kamusheva M, Petrova G, Onchev G. Costs and outcomes for individuals with psychosis prior to hospital admission and following discharge in Bulgaria. *Soc Psychiatry Psychiatr Epidemiol.* (2019) 54:1353–62. doi: 10.1007/s00127-019-01700-2
19. Calvert M, Blazey J, Altman DG, Revicki D, Moher D, Brundage M, et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. *JAMA.* (2013) 309:814–22. doi: 10.1001/jama.2013.8379
20. *National Center of Public Health Analysis. ICD.* Available online at: http://ncp.php.govt.bg/index.php?option=com_content&view=article&id=1431&catid=16&Itemid=632&Itemid=632&lang=bg
21. *International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10)-WHO Version for 2016.* Available online at: https://icd.who.int/browse10/2016/en#XII
22. Kamusheva M, Vassileva M, Savova M, Manova M Petrova G. An overview of the reimbursement decision-Making processes in Bulgaria as a reference country for the middle-Income european countries. *Front. Public Health.* (2018) 6:61. doi: 10.3389/fpubh.2018.00061
23. Fieffe S, Morange P, Petrossians P, Chanson V, Rohmer C, Cortet C, et al. Registry. Diabetes in acromegaly, prevalence, risk factors and evolution: data from the French Acromegaly Registry. *Eur J Endocrinol.* (2011) 164:877–84. doi: 10.1530/EJE-10-1050

24. Petersenn S, Buchfelder M, Gerbert B, Franz H, Quabbe HJ, Schulte HM, et al. Age and sex as predictors of biochemical activity in acromegaly: 131 analysis of 1485 patients from the german acromegaly register. *Clin Endocrinol.* (2009) 71:400–5. doi: 10.1111/j.1365-2265.2009.03547.x

25. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. *J Clin Endocrinol Metab.* (2004) 89:1613–7. doi: 10.1210/jc.2003-031584

26. Bex M, Abs R, T’Sjoen G, Mockel J, Velkeniers B, Muermans K, et al. AcroBel - the belgian registry on acromegaly: a survey of the ‘real-life’ outcome in 418 acromegalic subjects. *Eur J Endocrinol.* (2007) 157:399–409. doi: 10.1530/EJE-07-0358

27. Drange MR, Fram NR, Herman-Bonert V, Melmed S. Pituitary tumor registry: a novel clinical resource. *J Clin Endocrinol Metab.* (2000) 85:168–74. doi: 10.1210/jc.85.1.168

28. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. *J Clin Endocrinol Metab.* (2004) 89:667–74. doi: 10.1210/jc.2003-031199

29. Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. *Pituitary.* (1999) 2:29–41 doi: 10.1023/A:1009965803750

30. Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, et al. A nationwide survey of mortality in acromegaly. *J Clin Endocrinol Metab.* (2005) 90:4081–6. doi: 10.1210/jc.2004-1381

31. Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). *Eur J Endocrinol.* (2004) 151:439–6. doi: 10.1530/eje.0.1510439

32. Freda PU, Beckers AM, Katznelson L, Molitch ME, Montori VM, Post KD, et al. Pituitary incidentaloma: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab.* (2011) 96:9894–904. doi: 10.1210/jc.2010-1048

33. Colao A, Vandeva S, Pivonello R, Grasso L, Nachev E, Auriemma RS, et al. Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy). *Eur J Endocrinology.* (2014) 171:263–73. doi: 10.1530/EJE-13-1022

34. Arosio M, Reimondo G, Malchiodi E, Berchialla P, Borraccino A, De Marinis L, et al. Predictors of morbidity and mortality in acromegaly: an italian survey. *Eur J Endocrinol.* (2012) 167:189–98. doi: 10.1530/EJE-12-0084

35. Sesmilo G. Epidemiology of acromegaly in Spain. *Endocrinol Nutr.* (2013) 60:470–4. doi: 10.1016/j.endoen.2013.10.003

36. Vallette S, Ezzat S, Chik C, Ur E, Imran SA, Van Uum S, et al. Emerging trends in the diagnosis and treatment of acromegaly in canada. *Clin Endocrinol.* (2013) 79:79–85. doi: 10.1111/cen.12112

37. Kwon O, Song YD, Kim SY, Lee EJ. Nationwide survey of acromegaly in south korea. *Clin Endocrinol.* (2013) 78:577–85. doi: 10.1111/cen.12020

38. Schoff C, Franz H, Grussendorf M, Honegger J, Jaurisch-Hanck C, Mayr B, et al. Long-term outcome in patients with acromegaly: analysis of 1344 patients from the german acromegaly registry. *Eur J Endocrinol.* (2013) 168:39–47. doi: 10.1530/EJE-12-0602

39. Portocarrero-Ortiz LA, Vergara-Lopez A, Vidrio-Velazquez M, Uribe-Diaz AM, Garcia-Dominguez A, Reza-Albarrán AA, et al. The mexican acromegaly registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes. *J Clin Endocrinol Metab.* (2016) 101:3997–4004. doi: 10.1210/jc.2016-1937

40. Melmed S, Bronstein M, Chanson P, Klhanski A, Casanueva F, Wess J, et al. A consensus statement on acromegaly therapeutic outcomes. *Nat Rev Endocrinol.* (2018) 14:552–61. doi: 10.1038/s41574-018-0058-5

41. Carmichael JD, Bonert VS, Nuño M, Ly D, Melmed S, et al. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. *J Clin Endocrinol Metab.* (2014) 99:1825–33. doi: 10.1210/jc.2013-3757

42. Strasburger CJ, Mattsson A, Wilton P, Aydin F, Hey-Hadavi J, Biller BMK. Increasing frequency of combination medical therapy in the treatment of acromegaly with the gH receptor antagonist pegvisomant. *J Clin Endocrinol Metab.* (2018) 178:321–9. doi: 10.1530/EJE-17-0996

43. Lesén E, Granfeldt D, Houch ard A, Dinet J, Berthon A, Olsson DS, et al. Cost-of-Illness of acromegaly in sweden - a Register-Linkage population-Based study. *Value Health.* (2016) 19:A669. doi: 10.1016/j.jval.2016.05.918

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2020 Kamusheva, Vandeva, Mitov, Rusenova, Elenkova, Zacharieva, Mitkova, Tadkhov, Dimitrova, Doneva, Tcharaktchiev and Petrova. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*